Association of two tumour necrosis factor gene polymorphisms with the incidence of severe intraventricular haemorrhage in preterm infants

A Heep, A C Schueller, E Kattner, M Kroll, J Sander, M Wisbauer, P Bartmann, F Stueber

J Med Genet 2005;42:604–608. doi: 10.1136/jmg.2004.021378

The tumour necrosis factor (TNF) α and β gene pair is located in the human major histocompatibility complex between 6p21.1 and 6p21.3.^{1,2} Gene polymorphisms within the TNF α and TNF β gene are well described.^{3–7} The extent of TNF α expression has been shown to be associated with the overall allele frequency and genotype distribution of the NcoI restriction fragment length polymorphism in the first intron of the TNF β locus.^{8,9} In an in vitro endotoxin stimulation model, the extent of TNF expression has been correlated to the genotype of a single base polymorphism in the –308 promoter region of the TNF α gene.¹⁰ In contrast to this finding, the clinical importance of polymorphisms in the TNF α gene remains controversial. Survival in severe sepsis¹¹ has not been associated with genotype distribution of single base mutation in the –308 promoter region of the TNF α gene.

Focussing on neonatal morbidity, neither the development of chronic lung disease of prematurity¹² nor necrotising enterocolitis¹³ were correlated to genotype distribution of the TNF α gene, whereas the development of intraventricular haemorrhage (IVH) was correlated to the –308 promoter region polymorphism of the TNF α gene.¹² Genetic determination of the individual inflammatory response may influence the susceptibility to poor outcome after systemic infection or severe tissue damage.^{8,9,14}

Premature infants are at high risk of cerebral morbidity, which is associated with long term limitations and disability.¹⁵ Immaturity as well as a systemic perinatal inflammatory response^{16–22} play a major role in the pathogenesis of cerebral haemorrhage and white matter brain damage. Molecular markers predicting susceptibility to cerebral morbidity in premature infants are missing and thus prophylactic therapeutic strategies are still limited.

The aim of this study was to describe the frequency of two biallelic polymorphisms within the TNF locus in premature infants of <32 weeks gestation with severe IVH compared to healthy newborn infants without a history of cerebral morbidity.

METHODS

Study subjects

A retrospective cohort study was carried out on stored Guthrie blood spot cards stripped of all identifiers. The blood spot cards were from two groups of infants treated at the Department of Neonatology of the University of Bonn, Kinderkrankenhaus auf der Bult, Hannover, and Olghospital Stuttgart, Stuttgart, Germany between January 1999 and December 2000.

Group A comprised 27 premature infants of <32 weeks gestational age with sonographic finding of severe IVH at postnatal day 7. The sonographic findings of IVH were classified using the criteria given by Volpe¹⁵: (a) grade I (mild), germinal matrix haemorrhage with no or minimal

Key points

- There are no molecular markers predicting susceptibility to cerebral morbidity in premature infants and therapeutic strategies are still limited. Genetic polymorphisms in the tumour necrosis factor (TNF) gene modify TNF expression. A systemic perinatal inflammatory response is known to be a risk factor for severe intraventricular haemorrhage (IVH) in preterm infants.
- We studied the frequency of biallelic polymorphisms of the TNF α promoter region and the NcoI polymorphism of the TNF β gene in premature infants with severe IVH. The overall allele frequency and genotype distribution of the –308 TNF α polymorphism were comparable with values found in controls.
- The overall incidence of the TNF β 2 allele was higher in the IVH group compared to the control group. Genotype distribution of a polymorphic site within the TNF β locus in the male patient group significantly differed from distribution in the control group. Male patients showed a significantly higher prevalence of the homozygous genotype for the TNF β 2 allele.
- Our study results provide the first molecular link between TNF β gene polymorphism and the incidence of severe IVH in preterm infants.

IVH; (b) grade II (moderate), IVH (10–50% of ventricular area in parasagittal scan); (c) grade III (severe) (>50% of ventricular area in parasagittal scan); and (d) apparent periventricular haemorrhagic infarction. According to the classification given by Volpe, in our study severe IVH was defined as either grade III IVH or IVH with apparent periventricular haemorrhagic infarction.

Group B comprised 102 healthy newborn infants selected according to the study entry criteria (inborn patients, >32+0 weeks gestation, no signs of severe IVH on ultrasound examination at postnatal day 7).

All patients treated at the three study centres who met entry criteria were included into the study. TNF allele distribution of the study population was also compared to reference groups of healthy adult volunteers.²³ Following the approval of the ethical committee of the University of Bonn, a three step study protocol was performed.

First, patients were recruited from the hospital patient charts according to study entry criteria. Second, stored Guthrie blood spot cards from the study population were

Abbreviations: IVH, intraventricular haemorrhage; LPS, lipopolysaccharide; TNF, tumour necrosis factor

retrieved from the newborn screening laboratory. Third, the Guthrie blood spot cards were stripped of all identifiers and sent to the molecular genetic laboratory for analysis. Laboratory analysis and later data analysis were performed blind to personal data. All study procedures followed the 1975 Declaration of Helsinki revised in 2000.

Laboratory investigation

Human genomic DNA was extracted from stored Guthrie blood spot cards.²⁴⁻²⁸ For amplification of the 782 bp fragment of genomic DNA containing the polymorphic NcoI site within the TNF β locus, blood spot cards were immersed in a mixture containing 0.334 μ M each of primer 1 (5' CCGTGCTTCGT GCTTTGGACTA 3') and primer 2 (5' AGAGGGGTGGATGC TTGGGTTC 3'); PCR Premix E buffer (50 nM Tris-HCl, 50 mM KCl, 2.5 mM MgCl₂, and 200 μ M each of dATP, dTTP, dCTP, and dGTP) (Biozym, Oldendorf, Germany); and ddH₂O. To amplify the 264 bp fragment of the TNF α promoter -308 locus we used a mixture containing 0.4 μ M each of primer 1 (5' CCTGCATCCTGTCTGGAAGTTA 3') and primer 2 (5' CTGCACCTTCTGTCTCGGTTT 3'); 200 μ M each of dATP, dTTP, dCTP, and dGTP; and GeneAmp 10 $\times$ buffer (100 mM Tris-HCl, 500 mM KCl, 15 mM MgCl₂, and 0.01% w/v gelatine) (Perkin Elmer, Branchburg, NJ, USA). Filter papers with primers, buffer, and ddH₂O were exposed to the following two step incubation: four cycles of 3 min at 95°C and 3 min at 62°C. This program delivered DNA and reduced inhibition of PCR by free proteins and heavy metals. Afterwards, 1 U of Ampli Taq DNA polymerase (Perkin Elmer, Branchburg, NJ, USA) was added to the ice cold reaction products. The following protocol was used for PCR. For the TNF β product a denaturation step was conducted for 3 min at 95°C, followed by 43 cycles of 20 s denaturation at 95°C, 60 s annealing at 68°C, and 60 s extension at 72°C. Final extension was performed for 10 min at 72°C before analysing 10 μ l of amplified products by gel electrophoresis on a 1.6% agarose gel stained with 0.7 μ g/ml ethidium bromide. NcoI digestion was then performed with 5 μ l amplified DNA product. Digested DNA was again analysed by gel electrophoresis showing the original 782 bp fragment (homozygous patients for allele TNF β 2, lacking the NcoI site), three fragments of 782, 586, and 196 bp (heterozygous patients), or two fragments of 586 and 196 bp (patients homozygous for the allele TNF β 1).

The PCR protocol for the TNF α product included denaturation followed by 43 cycles of 20 s denaturation at 95°C, 60 s annealing at 64°C, and 30 s extension at 72°C. Final extension was performed for 7 min at 72°C. Gel electrophoresis showed the 264 bp fragment. Genotyping of the TNF α product was performed by analysing DNA melting curves in a real time PCR system (LightCycler, Roche, Mannheim, Germany). Therefore, we used 0.15 μ M each of anchor (5' RED640-CAAAACCTATTGCCTCCATTCTTTGGGGACph 3') and sensor (5' AACCCCGTCCCCATGCCCC-x 3') oligonucleotides (TIB MOLBIOL, Berlin, Germany). The latter included at position 10 the variable -308 nucleotide of the promoter region TNF α and was fully complementary only to the PCR product of TNF allele 1. Denaturation of the probes by rapid heating up to 95°C (Δ C/s = 20) was directly followed by a 25 s annealing step at 45°C while the fluorophore coupled oligonucleotides hybridised to adjacent regions of the target DNA. Fluorescein of the sensors 3' end which was excited by an external light source was now able to activate LightCycler RED640 on the 5' end of the anchor. The excited RED640 then emitted measurable light at 640 nm. During slow denaturation (95°C with Δ C/s = 0.2) binding of anchor and sensor to target DNA melts and fluorescence could not be observed. Since the sensor bound much more tightly to the PCR product of the TNF α allele 1, the melting temperature

was higher and could easily be distinguished from that of the TNF α allele 2. In case of heterozygosity two melting curve peaks were detectable.

Statistical analysis

Statistical analysis of the genotype distribution and allele frequency was carried out by χ^2 test with two sided p values to compare values between groups of patients. The groups were compared by estimating Hardy-Weinberg equilibrium.

RESULTS

Table 1 shows the genotype distribution of the TNF β and TNF α -308 genes in group A compared to group B and reference groups. Regarding the NcoI polymorphism of the TNF β gene, the genotype distribution in group A was no different from that of group B ($p < 0.06$). No difference between the groups was found for TNF α -308 genotype distribution.

When stratified by gender (table 2) a significant difference for the TNF β genotype distribution was found for male patients of group A compared to male patients of group B ($p < 0.04$).

Table 3 shows the TNF β 1/2 and TNF α promoter -308 allele distribution of group A compared to group B. The overall incidence of the TNF β 2 allele was significantly higher in group A compared to group B ($p < 0.01$). In male patients, TNF β 2 allele frequency was significantly elevated in group A compared to group B (table 4, $p < 0.01$), whereas no difference was found when comparing the TNF β 1/2 allele frequency of female patients (group A v group B, $p < 0.28$). No difference was found for the TNF α promoter -308 allele frequency within the groups.

The Hardy-Weinberg equilibrium of genotype distribution was estimated to compare group B and the reference groups. The genotype distribution of group B did not differ from the reference groups (TNF β : $p < 0.66$; TNF α -308: $p < 0.94$).

DISCUSSION

TNF α plays a pivotal role in the proinflammatory cytokine cascade.

The biallelic NcoI polymorphism within the TNF locus was shown to be a genomic marker for increased TNF α expression⁸⁻¹⁴ and outcome⁹ in adult patients with severe sepsis.

In the model of lipopolysaccharide (LPS) induced TNF α production by human monocytes in an ex vivo culture enhanced TNF α expression was found in relation to TNF α genotype.⁶

Table 1 Genotype distribution of TNF β and TNF α -308 variants in group A (n = 27) compared to group B (n = 102) and reference groups

	Genotype	Group A (n, %)	Group B (n, %)	Reference (n, %)*†
TNF β	1/1	1 (3, 7%)	18 (17, 7%)	35 (13, 9%)
	1/2	8 (29, 6%)	39 (38, 2%)	98 (38, 9%)
	2/2	18 (66, 7%)	45 (44, 1%)	119 (47, 2%)
Total		27 (100%)	102 (100%)	252 (100%)
p Value		$p < 0.06$		$p < 0.66$
TNF α promoter -308	1/1	19 (70, 4%)	68 (66, 7%)	151 (64, 8%)
	1/2	7 (25, 9%)	29 (28, 4%)	69 (29, 6%)
	2/2	1 (3, 7%)	5 (4, 9%)	13 (5, 6%)
Total		27 (100%)	102 (100%)	233 (100%)
p Value		$p < 0.92$		$p < 0.94$

Reference groups²³: *group 1 TNF β gene (n = 252); †group 2 TNF α -308 gene (n = 233).

Table 2 Genotype distribution by gender of TNF β and TNF α –308 genes in group A (n = 27) compared to group B (n = 102)

	Genotype	Group A male (n, %)	Group A female (n, %)	Group B male (n, %)	Group B female (n, %)
TNF β	1/1	1 (6, 7%)	0	10 (17, 5%)	8 (17, 8)
	1/2	2 (13, 3%)	6 (50%)	22 (38, 6%)	17 (37, 8)
	2/2	12 (80%)	6 (50%)	25 (43, 9%)	20 (44, 5)
Total		15 (100%)	12 (100%)	57 (100%)	45 (100)
p Value v control		p<0.04	p<0.28		
TNF α promoter –308	1/1	12 (80%)	7 (58, 3%)	37 (64, 9%)	31 (68, 9%)
	1/2	2 (13, 3%)	5 (41, 7%)	18 (31, 6%)	11 (24, 4%)
	2/2	1 (6, 7%)	0	2 (3, 5%)	3 (6, 7%)
Total		15 (100%)	12 (100%)	57 (100%)	45 (100%)
p Value v control		p<0.35	p<0.38		

Studies on TNF gene polymorphism in neurodegenerative diseases demonstrate that polymorphism in the TNF α gene (C850T) is a risk factor for the development of Alzheimer's disease and vascular dementia.³ In paediatric patients cerebral malaria was associated with a predominance of the homozygous TNF2 genotype.⁴

The ability of the neonate to react on LPS exposure with enhanced TNF α production was demonstrated by experimental data on TNF α release following LPS stimulation in an ex vivo cord blood culture model.²⁹

Studies on evaluation of TNF α for the early diagnosis of neonatal infection indicate that high expression of TNF α measured in the serum appears to be a highly sensitive and specific marker of sepsis in the early postnatal period.^{30–32} However, focusing on polymorphism in the TNF α and TNF β gene and specific neonatal morbidity only limited reports are available.^{12–13–33} In a study on neonates with proven sepsis, the biallelic NcoI polymorphism within the TNF α locus was not found to be a prognostic marker for disease progression.³³

Induction of TNF α release in the brain following hypoxic ischaemic encephalopathy or IVH was shown by TNF α measurements in the CSF and CSF/plasma ratios in newborn infants.^{34–36} From this finding one may assume that local enhanced inflammatory reaction is of certain importance in the pathogenesis of cerebral morbidity in the newborn infant.

The incidence of IVH in premature infants is independently related to gestational age and different perinatal morbidity.^{15–37} There is evidence that inflammatory umbilical cord lesions and elevated proinflammatory cytokine levels in the amniotic fluid or in the cord blood are associated with cerebral morbidity in newborn infants.^{16–18–20–21} Intrauterine T cell activation and increased inflammatory activity has been shown to be related to early postnatal changes of the cerebral white matter on magnetic resonance imaging.³⁸ In a clinical study on preterm infants of <28 weeks gestation¹⁹ early systemic inflammatory neonatal response measured by serum IL-6 was significantly correlated with the development of severe IVH independent of gestational age.

Table 3 TNF β and TNF α promoter –308 allele distribution (group A v group B)

	Allele	Group A, n = 54 (n, %)	Group B, n = 204 (n, %)
TNF β	1	10 (18, 5%)	75 (36, 8%)
	2	44 (81, 5%)	129 (63, 2%)
p Value		0.01	
TNF α promoter –308	1	45 (83, 3%)	165 (80, 9%)
	2	9 (16, 7%)	39 (19, 1%)
p Value		0.68	

Studies on human cerebral microvascular endothelial cells indicate that these are capable of up-regulating inflammatory endothelial mediators in response to proinflammatory cytokines or ischaemia.³⁹ Consecutive pathophysiological steps are vasoparalysis³⁹ and activation of microglial cytokine expression.^{40–44}

Haemodynamic disturbances are known to be related to cerebral morbidity in preterm infants.^{15–45} Recently, a study showed correlation of systemic fetal inflammation (chorioamnionitis, elevated proinflammatory cord blood cytokines) with reduction of systemic blood pressure, cardiac output, and increased incidence of severe IVH in premature infants.⁴⁶

Taking the experimental and clinical findings as a basis, one may speculate that polymorphisms in the TNF genome that distinctly contribute to TNF α release may lead to haemodynamic changes and by inducing cytotoxic cerebral microvascular damage⁴⁷ thereby lead to severe IVH.

We studied two different gene polymorphisms within the TNF α and TNF β gene to investigate genotype distribution in correlation to the incidence of severe IVH in preterm infants. The study group was stratified by gender as male gender is a known perinatal risk factor in the pathogenesis of severe IVH.⁴⁸

One previous report describes correlation of single base polymorphism in the –308 promoter region of the TNF α gene with the incidence of IVH in premature infants.¹² In contrast to this finding, in our study, the distribution of TNF α promoter –308 polymorphism was not different within the study groups and no difference was found with regards to gender.

The overall frequency of the TNF β 2 allele in group A was found to be elevated compared to group B. The TNF β 2 genotype in male patients indicated a significant risk of severe IVH in patients of <32 weeks gestation.

Although the study results are limited by the small number of patients included, it extends observations which associate the TNF β 2 allele distribution with illness severity of patients in intensive care. Our study is the first to indicate that a predominance of the TNF β 2 allele and genotype of a proinflammatory cytokine such as TNF in male gender is linked to a major neuropathological outcome parameter in premature infants.

Etiologic research, stratifying premature infants at risk of cerebral morbidity following perinatal risk factors, is necessary to elucidate the significance of the genetic background as an independently predictive variable in the complex pathophysiological sequence leading to cerebral morbidity in preterm infants.

ACKNOWLEDGEMENTS

We gratefully acknowledge the skilled technical assistance of Alexandra Casalter and the revision of genetic statistics by Rolf Fimmers.

Table 4 TNF β 1/2 and TNF α promoter -308 allele distribution of male and female patients (group A v group B)

	Allele	Group A male, n = 30 (n, %)	Group B male, n = 114 (n, %)	Group A female, n = 24 (n, %)	Group B female, n = 90 (n, %)
TNF β	1	4 (13, 3%)	42 (36, 8%)	6 (25%)	33 (36, 7%)
	2	26 (86, 7%)	72 (63, 2%)	18 (75%)	57 (63, 3%)
p Value		0.01		0.28	
TNF α promoter -308	1	26 (86, 7%)	92 (80, 7%)	19 (79, 2%)	73 (81, 1%)
	2	4 (13, 3%)	22 (19, 3%)	5 (20, 8%)	17 (18, 9%)
p Value		0.45		0.83	

Authors' affiliations

A Heep, A C Schueller, M Wisbauer, P Bartmann, Department of Neonatology, University of Bonn, Bonn, Germany
E Kattner, Kinderkrankenhaus auf der Bult, Hanover, Germany
M Kroll, Department of Neonatal Intensive Care, Olgahospital, Stuttgart, Germany
J Sander, Screeninglabor, Hanover, Germany
F Stueber, Department of Anaesthesiology and Intensive Care Medicine, University of Bonn, Bonn, Germany

Competing interests: none declared

Correspondence to: Dr Axel Heep, Department of Neonatology, University of Bonn, Adenauerallee 119, D-53113 Bonn, Germany; a.heep@uni-bonn.de

Revised version received 17 May 2004

Accepted for publication 17 May

REFERENCES

- Carroll MC, Katzman P, Alicot EM, Koller BH, Geraghty DE, Orr HT, Strominger JL, Spies T. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. *Proc Natl Acad Sci U S A* 1987;**84**:8535.
- Nedwin GE, Naylor SL, Sakaguchi AY, Smith D, Jarrett-Nedwin J, Pennica D, Goeddel DV, Gray PW. Human lymphotoxin and tumor necrosis factor genes: structure, homology, and chromosomal localization. *Nucleic Acids Res* 1985;**13**:6361-73.
- McCusker SM, Curran MD, Dynan KB, McCullagh CD, Urquhart DD, Middleton D, Patterson CC, McIlroy SP, Passmore AP. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. *Lancet* 2001;**357**:436-9.
- McGuire W, Hill AVS, Allsopp CEM, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. *Nature* 1994;**371**:508-11.
- Messer G, Spengler U, Jung MC, Hunold G, Blömer K, Pape GR, Riettmüller G, Weiss EH. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-alpha production. *J Exp Med* 1991;**173**:209-19.
- Pociot F, Briant L, Jongeneel CV, Molvig J, Worsaae H, Abbal M, Thomsen M, Neup J, Cambon-Thomson A. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. *Eur J Immunol* 1993;**23**:224-31.
- Wilson AG, di Giovine FS, Blakemore AIF, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF α) gene detectable by NcoI restriction of PCR product. *Hum Mol Genet* 1992;**1**:353.
- Majetschak M, Flohé S, Obertacke U, Schröder J, Staubach K, Nast-Kolb D, Schade U, Stüber F. Relation of a TNF gene polymorphism to severe sepsis in trauma patients. *Ann Surg* 1999;**230**:207-14.
- Stueber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. *Crit Care Med* 1996;**24**:381-84.
- Bouma G, Crusius JB, Oudkerk Pool M, Kolkman JJ, von Blomberg BM, Kostense PJ, Giphart MJ, Schreuder GM, Meuwissen SG, Pena AS. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. *Scand J Immunol* 1996;**43**:456-63.
- Stueber F, Udalova IA, Book M, Drutskaya LN, Kuprash DV, Turetskaya RL, Schade FU, Nedospasov SA. -308 Tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. *J Inflamm* 1996;**46**:42-50.
- Adcock K, Hedberg C, Loggins J, Kruger TE, Baier RJ. The TNF-alpha-308, MCP-1 -2518 and TGF-beta-1 +915 polymorphisms are not associated with the development of chronic lung disease in very low birth weight infants. *Genes Immun* 2003;**4**:420-6.
- Treszl A, Kocis I, Szathmari M, Schuler A, Tulassay T, Vasarhelyi B. Genetic variants of the tumour necrosis factor-alpha promoter gene do not influence the development of necrotizing enterocolitis. *Acta Paediatr* 2001;**90**:1182-5.
- Shu Q, Fang X, Stueber F. Association of tumor necrosis factor microsatellite polymorphism with the incidence and outcome of severe postoperative sepsis. *Zhonghua Yi Xue Za Zhi* 2000;**80**:193-5.
- Volpe JJ. Intracranial hemorrhage: germinal matrix-intraventricular hemorrhage of the premature infant. In: Volpe JJ, eds. *Neurology of the newborn*. Philadelphia, PA: WB Saunders, 2001:428-93.
- Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. *Pediatr Res* 1997;**42**:1-8.
- Dammann O, Leviton A. Infection remote from the brain, neonatal white matter damage, and cerebral palsy in the preterm infant. *Semin Pediatr Neurol* 1998;**5**(3):190-201.
- Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. *Am J Obstet Gynecol* 1998;**179**:194-202.
- Heep A, Behrendt D, Nitsch P, Fimmers R, Bartmann P, Dembinski J. Increased serum levels of interleukin 6 are associated with severe intraventricular haemorrhage in extremely premature infants. *Arch Dis Child* 2003;**88**:F501-4.
- Tauscher MK, Berg D, Brockmann M, Seidenspinner S, Speer CP, Groneck P. Association of histologic chorioamnionitis, increased levels of cord blood cytokines and intraventricular hemorrhage in preterm neonates. *Biol Neonate* 2003;**83**:166-70.
- Yoon BH, Jun JK, Romero R, Park KH, Gomez R, Choi JH, Kim IO. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. *Am J Obstet Gynecol* 1997;**177**:19-26.
- Yoon BH, Romero R, Kim CJ, Koo JN, Choe G, Syn HC, Chi JG. High expression of tumor necrosis factor-alpha and interleukin-6 in periventricular leukomalacia. *Am J Obstet Gynecol* 1997;**177**:406-11.
- Stueber F. TNF alpha promoter -308 and TNF beta allele distribution. A cohort of healthy German blood donors, unpublished data, 2001.
- McCabe ERB, Huang S-Z, Seltzer WK, Law ML. DNA microextraction from dried blood spots on filter paper blotters: potential applications to newborn screening. *Hum Genet* 1987;**75**:213-6.
- Nelson PV, Carey WF, Morris CP. Gene amplification directly from Guthrie blood spots. *Lancet* 1990;**336**:1451-2.
- Raskin S, Phillips JA, Kaplan G, McClure M, Vnencak-Jones C. Cystic fibrosis genotyping by direct PCR analysis of Guthrie blood spots. *PCR Methods Appl* 1992;**2**:154-6.
- Rubin EM, Keith AA, Wai Kan Y. Newborn screening by DNA analysis of dried blood spots. *Hum Genet* 1989;**82**:134-6.
- Schwartz EI, Khalchitsky SE, Eisensmith RC, Woo SCL. Polymerase chain reaction amplification from dried blood spots on Guthrie cards. *Lancet* 1990;**336**:639-40.
- Dembinski J, Behrendt D, Martini R, Heep A, Bartmann P. Modulation of pro- and anti-inflammatory cytokine production in very premature infants. *Cytokine* 2003;**21**:200-6.
- Girardin EP, Berner ME, Grau GE, Suter S, Lacourt G, Paunier L. Serum tumour necrosis factor in newborn at risk for infections. *Eur J Pediatr* 1990;**149**:645-7.
- Roman J, Fernandez F, Velasco F, Rojas R, Roldan MR, Torres A. Serum TNF levels in neonatal sepsis and septic shock. *Acta Paediatr* 1993;**82**:352-4.
- Silveira RC, Procanoy RS. Evaluation of interleukin-6, tumour necrosis factor-alpha and interleukin-1beta for early diagnosis of neonatal sepsis. *Acta Paediatr* 1999;**88**:647-50.
- Weitkamp JH, Stüber F, Bartmann P. Pilot study assessing TNF gene polymorphism as a prognostic marker for disease progression in neonates with sepsis. *Infection* 2000;**28**:92-6.
- Savman K, Blennow M, Gustafson K, Tarkowski E, Hagberg H. Cytokine response in the cerebrospinal fluid after birth asphyxia. *Pediatr Res* 1998;**43**:746-51.
- Silveira RC, Procanoy RS. Interleukin-6 and tumor necrosis factor alpha levels in plasma and cerebrospinal fluid of term newborn infants with hypoxic-ischemic encephalopathy. *J Pediatr* 2003;**143**:625-9.
- Savman K, Blennow M, Hagberg H, Tarkowski E, Thoresen M, Whitelaw A. Cytokine response in the cerebrospinal fluid from preterm infants with posthaemorrhagic ventricular dilatation. *Acta Paediatr* 2002;**91**:1357-63.
- Salafia CM, Miniou VK, Rosenkrantz TS, Pezzullo JC, Popek EJ, Cusick W, Vintzileos AM. Maternal, placental and neonatal associations with early germinal matrix/intraventricular hemorrhage in infants born before 32 wk gestation. *Am J Perinatol* 1995;**12**:429-36.
- Duggan PJ, Edwards AD. Placental inflammation and brain injury in preterm infants. *Dev Med Child Neurol* 2001;**86**:16-7.

- 39 Stanimirovic D, Satoh K. Inflammatory mediators of cerebral endothelium. *Brain Pathol* 2000;**10**:113–26.
- 40 Acarin L, Gonzales B, Castellano B. Neuronal astroglial and microglial cytokine expression after an excitotoxic lesion in the immature rat brain. *Eur J Neurosci* 2000;**12**:3505–20.
- 41 Eklind S, Maillard C, Leverin AL, Gilland E, Blomgren K, Mattsby-Baltzer I, Hagberg H. Bacterial endotoxin sensitizes the immature brain to hypoxic-ischaemic injury. *Eur J Neurosci* 2001;**13**:1101–6.
- 42 Van Dam AM, Bauer J, Tilders FJH, Berkenbosch F. Endotoxin-induced appearance of immunoreactive interleukin-1 β in ramified microglia in rat brain: a light and electron microscopic study. *Neuroscience* 1995;**65**:815–26.
- 43 Raivich G, Jones LL, Werner A, Bluthmann H, Doetschmann T, Kreutzberg GW. Molecular signals for glial activation: pro- and anti-inflammatory cytokines in the injured brain. *Acta Neurochir Suppl* 1999;**73**:21–30.
- 44 Suzuki S, Tanaka K, Nogawa S, Nagata E, Ito D, Dembo T, Fukuuchi Y. Temporal profile and cellular localization of interleukin-6 protein after focal cerebral ischemia in rats. *J Cereb Blood Flow Metab* 1999;**19**:1256–62.
- 45 Bada H, Korones S, Perry E, Arheart K, Ray J, Pourcyrous M, Magill H, Runyan W, Simes G, Clark F, Tullis K. Mean arterial blood pressure changes in premature infants and those at risk for intraventricular hemorrhage. *J Pediatr* 1990;**117**:607–14.
- 46 Yanowitz TD, Jordan JA, Gilmour CH, Towbin R, Bowen A, Roberts JM, Brozanski BS. Hemodynamic disturbances in premature infants born after chorioamnionitis: association with cord blood cytokine concentrations. *Pediatr Res* 2002;**51**:310–6.
- 47 Kimura H, Gules I, Meguro T, Zhang JH. Cytotoxicity of cytokines in cerebral microvascular endothelial cell. *Brain Res* 2003;**990**:148–56.
- 48 Heuchan AM, Evans N, Henderson Smart DJ, Simpson JM. Perinatal risk factors for major intraventricular haemorrhage in the Australian and New Zealand Neonatal Network, 1995–97. *Arch Dis Child* 2002;**86**:F86–90.

Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. *Clinical Evidence* needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

Areas for which we are currently seeking authors:

- Child health: nocturnal enuresis
- Eye disorders: bacterial conjunctivitis
- Male health: prostate cancer (metastatic)
- Women's health: pre-menstrual syndrome; pyelonephritis in non-pregnant women

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with *Clinical Evidence* editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every six months using any new, sound evidence that becomes available. The *Clinical Evidence* in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.
- To expand the topic to include a new question about once every 12–18 months.

If you would like to become a contributor for *Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Klara Brunnhuber (kbrunnhuber@bmjgroup.com).

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for *Clinical Evidence*, please complete the peer review questionnaire at www.clinicalevidence.com or contact Klara Brunnhuber (kbrunnhuber@bmjgroup.com).